Last reviewed · How we verify
ASPARAGINASE ERWINIA CHRYSANTHEMI
RYLAZE kills leukemic cells by depleting plasma asparagine, which they need for survival.
At a glance
| Generic name | ASPARAGINASE ERWINIA CHRYSANTHEMI |
|---|---|
| Drug class | Asparagine-specific Enzyme [EPC] |
| Target | L-asparagine |
| Modality | Enzyme |
| Phase | FDA-approved |
| First approval | 2011 |
Mechanism of action
RYLAZE is an enzyme that converts L-asparagine into aspartic acid and ammonia. This depletion of asparagine in the blood starves leukemic cells, which rely on external sources of asparagine because they can't produce enough themselves.
Approved indications
Common side effects
- abnormal liver test
- abnormal liver test
- musculoskeletal pain
- musculoskeletal pain
- nausea
- nausea
- fatigue
- fatigue
- headache
- headache
- infection
- infection
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL (PHASE2)
- Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (PHASE2)
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (PHASE2)
- Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia (PHASE1)
- Venetoclax Basket Trial for High Risk Hematologic Malignancies (PHASE1)
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASPARAGINASE ERWINIA CHRYSANTHEMI CI brief — competitive landscape report
- ASPARAGINASE ERWINIA CHRYSANTHEMI updates RSS · CI watch RSS